This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Rieder, R. J.
Right arrow Articles by Zavizion, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rieder, R. J.
Right arrow Articles by Zavizion, B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2009, p. 4598-4603, Vol. 53, No. 11
0066-4804/09/$08.00+0     doi:10.1128/AAC.00643-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

New Approach for Drug Susceptibility Testing: Monitoring the Stress Response of Mycobacteria{triangledown}

Ronald J. Rieder,* Zhihui Zhao, and Boris Zavizion

BioSense Technologies, Inc., Woburn, Massachusetts

Received 12 May 2009/ Returned for modification 5 July 2009/ Accepted 18 August 2009

Methods currently used for in vitro drug susceptibility testing are based on the assessment of bacterial growth-related processes. This reliance on cellular reproduction leads to prolonged incubation times, particularly for slowly growing organisms such as mycobacteria. A new rapid phenotypic method for the drug susceptibility testing of mycobacteria is described. The method is based on the detection of the physiological stress developed by susceptible mycobacterial cells in the presence of an antimicrobial compound. The induced stress was quantified by differential monitoring of the dielectric properties of the bacterial suspension, an easily measurable electronic property. The data presented here characterize the stress developed by Mycobacterium tuberculosis cells treated with rifampin (rifampicin), isoniazid, ethambutol, and pyrazinamide. Changes in the dielectric-based profiles of the drug-treated bacteria revealed the respective susceptibilities in near real time, and the susceptibilities were well correlated with conventional susceptibility test data.

* Corresponding author. Mailing address: BioSense Technologies, Inc., 4 Arrow Drive, Woburn, MA 01801. Phone: (781) 933-3635. Fax: (208) 498-3920. E-mail: rieder{at}biosensetech.com

{triangledown} Published ahead of print on 24 August 2009.

Antimicrobial Agents and Chemotherapy, November 2009, p. 4598-4603, Vol. 53, No. 11
0066-4804/09/$08.00+0     doi:10.1128/AAC.00643-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»